Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA) (20 mg/kg/d for 20 days) vs placebo + IVMA
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found